14-day Premium Trial Subscription Sign Up For FreeGet Free

Weaker Stock
Today CLLS ranks #18343 as sell candidate. Get a Free Stock at Robinhood
Stronger Stock

Cellectis S.A. Stock Forecast NASDAQ:CLLS

$6.70 (-2.33%)

Volume: 231k

Closed: Jan 19, 2022

Hollow Logo Score: -6.498

Cellectis S.A. Stock Forecast

$6.70 (-2.33%)

Volume: 231k

Closed: Jan 19, 2022

Score Hollow Logo -6.498

Cellectis S.A. Company Profile

8, rue de la Croix Jarry

Paris 75013

33 1 81 69 16 00


Industry: Biotechnology

Sector: Healthcare

Cellectis S.A.


Cellectis S.A., a gene-editing company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. Its lead product candidate is UCART19, an allogeneic T-cell product candidate for the treatment of CD19 expressing hematologic malignancies which develop in acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia. The company’s products also include UCART123 for acute myeloid leukemia indications and blastic plasmacytoid dendritic cell neoplasm; UCARTCS1 for multiple myeloma (MM) indications; UCART38 for T-cell ALL and MM; and UCART22 for ALL. It has strategic alliances with Pfizer Inc. to generate CAR T-cells in the field of oncology; Les Laboratoires Servier SAS to develop and commercialize product candidates; and The University of Texas MD Anderson Cancer Center to research and develop novel cellular immunotherapies for patients suffering from various types of liquid tumors. Cellectis S.A. was founded in 1999 and is based in Paris, France.

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE